Back to top
more

Argenx (ARGX)

(Real Time Quote from BATS)

$457.51 USD

457.51
320,519

+21.09 (4.83%)

Updated Jul 9, 2024 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.

5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

by Zacks Equity Research

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

by Zacks Equity Research

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.

    Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

    by Zacks Equity Research

    Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

    argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

    by Zacks Equity Research

    argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

    Should You Buy argenx SE (ARGX) Ahead of Earnings?

    by Zacks Equity Research

    argenx SE (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Materialise (MTLS) to Report Q4 Earnings: What's in Store?

    by Zacks Equity Research

    Materialise's (MTLS) fourth-quarter 2021 earnings are likely to have benefited from solid operational performance in all three segments.

    Splunk (SPLK) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Splunk's (SPLK) fourth-quarter fiscal 2022 performance is likely to have benefited from solid demand for cloud-based solutions and customer additions.

    SEMrush (SEMR) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    SEMrush's (SEMR) fourth-quarter 2021 performance is likely to have benefited from growth in user licenses per customer along with strength in product add-ons.

    Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

    by Zacks Equity Research

    The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

    argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

    by Zacks Equity Research

    argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

    Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

    by Zacks Equity Research

    Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

    Immunovant Up on Positive Data From Myasthenia Gravis Study

    by Zacks Equity Research

    Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.

    argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

    by Zacks Equity Research

    argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    argenx Up on Positive Data from Pivotal Efgartigimod Study

    by Zacks Equity Research

    argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

    Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

    by Zacks Equity Research

    The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

    Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates

    by Zacks Equity Research

    Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

    Top Ranked Momentum Stocks to Buy for February 27th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 27th

    Why Earnings Season Could Be Great for argenx (ARGX)?

    by Zacks Equity Research

    argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX)

    by Zacks Equity Research

    Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Company News For Dec 12, 2017

    by Zacks Equity Research

    Companies in the news are: KMG,ARGX,BPMC,BLUE

      Company News for June 13, 2017

      by Zacks Equity Research

      Companies in the News are: WCST,CACI,TWX,ARGX